Teva Pharmaceutical Industries Limited (TEVA) |
14.11 -0.32 (-2.22%) 03-28 16:00 |
Open: | 14.35 |
High: | 14.41 |
Low: | 13.97 |
Volume: | 10,246,622 |
Market Cap: | 15,817(M) |
PE Ratio: | -28.22 |
Exchange: | New York Stock Exchange |
Industry: | Drug Manufacturers - Specialty & Generic |
Sector: | Healthcare |
Technical analysis | ||||
sell | buy |
Resistance 2: | 16.88 |
Resistance 1: | 14.45 |
Pivot price: | 13.70 |
Support 1: | 13.31 |
Support 2: | 12.61 |
52w High: | 14.45 |
52w Low: | 7.09 |
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.
EPS | -0.500 |
Book Value | 6.700 |
PEG Ratio | 3.58 |
Gross Profit | 0.000 |
Profit Margin (%) | -3.53 |
Operating Margin (%) | 28.05 |
Return on Assets (ttm) | 4.5 |
Return on Equity (ttm) | -7.4 |
Fri, 29 Mar 2024
Brokers Set Expectations for Teva Pharmaceutical Industries Limited's Q3 2025 Earnings (NYSE:TEVA) - MarketBeat
Wed, 27 Mar 2024
Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Acquired by Wellington Management Group LLP - MarketBeat
Tue, 26 Mar 2024
Teva Pharmaceutical Industries (NYSE:TEVA) Has A Somewhat Strained Balance Sheet - Simply Wall St
Tue, 26 Mar 2024
Institutional investors have a lot riding on Teva Pharmaceutical Industries Limited (NYSE:TEVA) with 67% ownership - Yahoo Finance
Mon, 25 Mar 2024
Teva Pharmaceutical Industries: Potential Outweighs Concerns (NYSE:TEVA) - Seeking Alpha
Mon, 25 Mar 2024
FTC weighs in on Teva's inhaler litigation against Amneal amid far-reaching patent crackdown - FiercePharma
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |